

### **THE NATURETIC EFFECTS OF LONG-TERM USE of MIDODRINE ON PATIENTS WITH LIVER CIRRHOSIS.**

#### **Abstract**

**Background:** splanchnic vasodilatation is a major contributor to development of ascites in cirrhotic patients and associated with poor sodium excretion. SO MIDODRINE which is, alpha 1 agonist, may improve circulatory abnormality in cirrhotic patients via its vaso-constrictive action thus leading to better natriuresis.

**Aim:** to assess the efficacy and the safety of midodrine (alpha adrenergic agonist) on patients with liver cirrhosis as regard sodium excretion.

**Patients and Methods:** A total of 80 cirrhotic patients with refractory ascites were enrolled in this prospective study. Patients consisted of 40 patients receiving standard medical therapy (dietary salt restriction and diuretics) and 40 patients receiving standard medical therapy +MIDODRINE in a dose of (7.5 mg /8hours) for one month. Body weight, abdominal girth, complete blood count, liver and renal function tests, serum electrolytes and 24-h urine volume and Na level were obtained at the start and the end of the study

**Results:** Body weight and abdominal girth significantly decreased in midodrine group patients compared to control group ( $p < 0.001$ ). Also, 24-h urinary volume and Na excretion were significantly higher in midodrine group patients at the end of the study compared to SMT patients ( $p < 0.001$ ).

**Conclusions:** MIDODRINE could be used safely as an adjuvant to SMT in cirrhotic patients with refractory ascites with better outcomes evidenced by reduced body weight and increase Na excretion in urine.

**Keywords:** cirrhosis, ascites, MIDODRINE, natriuresis

#### **Introduction**

Ascites is a common, serious consequence of cirrhosis and the patient becomes susceptible to complications <sup>(1)</sup>.

Hemodynamic compensation mechanisms include RAAS system and sympathetic nervous system activation and ADH release in response to systemic hypotension caused by splanchnic and systemic vasodilatation due to excess nitric oxide with subsequent dilutional hyponatremia associated with poor urinary sodium excretion. <sup>(2)</sup>

Midodrine, an alpha-1 agonist, decreases nitrite and nitrate activity in ascetic patients with HRS and plasma renin activity along with antidiuretic hormone levels also decline. <sup>(3)</sup>.

## Patients and methods

**Study design and patients:** This study was a prospective study during the period from April 2021 to March 2022. (Approval number 34461/2/2021).

A total of 80 patients either as an inpatient or outpatient were enrolled in this study. They were collected from the Department of Tropical medicine and infectious diseases, Tanta university hospital, Egypt. Patients were divided into 40 cirrhotic patients with refractory ascites receiving standard medical therapy (SMT) as a control group and 40 cirrhotic patients with refractory ascites receiving SMT+ MIDODRINE 2.5 mg (3 tablets / 8 hours) for 1 month. Traditional treatment included salt restriction to less than 90 mmol/day and diuretics spironolactone up to 400 mg /day and furosemide up to 160 mg /day or as tolerated provided that no complications as hepatic encephalopathy, hypokalemia, hyponatremia, impaired renal functions had occurred. Plus, large volume paracentesis (LVP).

The inclusion criteria were cirrhotic patients more than 18 years of age of any etiology and refractory ascites as defined according to European Association for the study of the liver <sup>(4)</sup>

The exclusion criteria were: (1) Patients with acute or chronic renal disease. (2) Patients with cardiac disease as coronary heart disease, abnormal blood pressure and congestive heart failure. (3) Hepatocellular carcinoma. (4) Portal vein thrombosis. (5) Patient unwilling to participate in the study.

All participants gave their informed written consents and the study was approved by the Research Ethics Committee of the Faculty of Medicine, Tanta University, Tanta, Egypt (approval number 34461/2/2021).

All authors had access to the study data and reviewed and approved the final manuscript.

**Methods:** All participants in the study were subjected to the following:

1- Full history taking and through clinical examination including frequency of tapping, body weight and abdominal girth measurement. 2- Laboratory investigations including complete blood count, liver function tests, renal function tests, serum electrolytes and 24-hour urine volume and Na excretion. 3- Child-Pugh score was assessed for all cirrhotic patients. 4- Abdominal ultrasonography.

Participants were randomized to either the intervention (midodrine) or the control group and the physical examination and the laboratory investigations were repeated after one month of the study to assess the effect of midodrine in the degree of ascites as well as its possible side effects

## Statistical analysis:

With the use of the IBM SPSS software package version 20.0, data were input into the computer (Armonk, NY: IBM Corp) and Qualitative data were described using number and percent. The Shapiro-Wilk test was used to verify the normality of distribution Quantitative data were described using range (minimum and maximum), mean, standard deviation, median and interquartile range (IQR). Significance of the obtained results was judged at the 5% level. The used tests were (1) Chi-square test For categorical variables, to compare between different groups (2) Fisher's Exact or Monte Carlo correction for correction of chi-square when more than 20% of

the cells have expected count less than 5(3) Student t-test For normally distributed quantitative variables, to compare between two studied groups (4) Mann Whitney test For abnormally distributed quantitative variables, to compare between two studied group (5) McNamar and Marginal Homogeneity Test Used to analyze the significance between the different stages (6) Paired t-test For normally distributed quantitative variables, to compare between two periods (7)Wilcoxon signed ranks test For abnormally distributed quantitative variables, to compare between two periods.

**Results:** A total of 80 cirrhotic patients with refractory ascites were enrolled in this prospective study. Patients consisted of 40 patients receiving standard medical therapy (SMT) and 40 patients receiving SMT +MIDODRINE. The demographic, baseline clinical and laboratory findings of the studied groups were summarized in **(Table 1)**.

Only 37 patients completed the study to its end in each group. In control group there were 2 patients who did not adhere for follow up and 1 patient who died of hepatorenal syndrome. While in group II, there was 1 patient stopped the drug after development of epistaxis, another did not show for follow up and another patient died also due to development of hepatorenal syndrome as shown in **figure (1)**

There were no significant differences between the studied groups as regards age and gender. As regard the etiology of cirrhosis, we found that the main etiology of cirrhosis is hepatitis C in both groups then comes bilharziasis.

It was found that there was no difference between the two studied groups as regard the etiology of cirrhosis. As regard diuretic intake it was found that there was no significance between the two studied groups as regard furosemide intake. While there was significant difference between the two groups as regard spironolactone intake at baseline.

As regard to tapping, it was found that there was no significance between the two studied groups at baseline but there was significant decrease in frequency of tapping among midodrine group patients which was not found in control group (P value =0.021) **(table 3)**

As regard occurrence of hepatic encephalopathy, there was significant difference between the two studied groups at the end of the study where there were 2 patients developed hepatic encephalopathy in group II while 8 patients developed hepatic encephalopathy in group I before the end of the study(P<0.001) **(table 2)**

As regard body weight, there was no significant difference between two studied groups at baseline but there was significant decrease in average body weight among midodrine group patients which did not happen in control patients(P<0.001) **(Table 3)**

As regard abdominal girth, it was found that there was significant difference between the two groups with more reduction in average abdominal girth in midodrine patients than in control patients(P<0.001) **(Table 3)**

As regard lower limb edema, there was significant decrease in both groups at the end of the study compared to baseline (P<0.001) **(table 2)**. But this decrease was much marked in midodrine patients than in control patients **(Table 3)**

As regard blood pressure, it was found that both systolic and diastolic blood pressure higher in midodrine patients at the end of the study(P<0.001)

There was no significant difference between the two studied groups either at baseline or at the end of the study as regard hemoglobin level, total leucocytic count, serum Na level, serum K level, total bilirubin, serum creatinine, blood urea, and serum albumin, ALT, AST and INR **(Table 4)**. There was no significant difference between both groups as regard urine volume and urinary Na level at baseline **(Table 1)** but there was significant increase in both values in midodrine group patients than in control group patients at the end of the month of the study (P<0.001) **(Table 5)**

## Discussion:

The distinction between the two studied groups as regard the etiology of cirrhosis. Consistent with the findings of (Obiedallah et al., 2017)<sup>(5)</sup>, another study which was conducted in 2017 and both studies were done in Egypt where liver cirrhosis is mostly caused by HCV. (Gomaa et al., 2017)<sup>(6)</sup>. There was significant difference between the two groups as regard spironolactone intake with 38 patients in group I and 34 patients in group II Which was attributed to randomization of the patients and side effects of diuretics in which spironolactone induced hyperkalemia is the most prominent as shown at (Angeli et al., 2010)<sup>7</sup>. Hepatic encephalopathy occurred in just 2 of group II's patients, compared to 8 of group I's patients. during the study. In another similar study (Singh et al., 2012)<sup>8</sup> 4 patients of 20 developed hepatic encephalopathy while receiving standard medical treatment while 3 patients of 20 developed HE in the midodrine group but this study was for longer duration for 3 months.

Regarding tapping, no significant difference was identified between the groups at baseline, however there was a marked decline in tapping frequency across the board for everyone. This decline, however, was noticeably more pronounced in the midodrine group than in the control group. These findings contrast with those of a similar research. (Obiedallah et al., 2017)<sup>6</sup> which found no significant improvement in both frequency and volume of ascetic fluid drained after 1 month of use of midodrine plus standard medical therapy. Regarding body weight, it was found that mean body weight in group I was less than group II due to randomization. And it significantly decreased in midodrine group at the end of the study which did not happen in control group. other results appeared in another study (Kalambokis et al., 2007)<sup>9</sup>, though the reduction in the body weight was not statistically significant but the study was only for 7 days. Also, Singh et al., 2012<sup>8</sup>, Ali et al., 2014<sup>10</sup> and Obiedallah et al., 2017<sup>6</sup> agreed with our results.

Regarding abdominal girth, before the study began, there was a large gap between the two groups of the study due to randomization and the average abdominal girth in midodrine group has significantly decreased but still higher than that of group I in which there was no significant reduction. The findings were backed up by the results of (Ali et al., 2014)<sup>10</sup> where the reduction in abdominal girths detected in midodrine group after 2 weeks of Midodrine therapy. Regarding blood pressure, both systolic and diastolic blood pressure were found to be higher on average in group II compared to group I. at the end of the study and this is attributed to vasoconstrictor effects of midodrine.

These results were supported by (Rai et al., 2017)<sup>11</sup> which used midodrine and tolvaptan on different groups. Also, same results appeared in another study (Angeli et al., 1998)<sup>12</sup> but it studied the acute effects of oral midodrine on hemodynamics of cirrhotic patients.

Another study showed the same results (Tandon et al., 2009)<sup>13</sup> but it used different doses of Midodrine. Regarding serum sodium and potassium, at the end of the experiment, there was no discernible difference between the two groups.

(Singh et al., 2012)<sup>8</sup> Demonstrated, contrary to our findings, that serum sodium reduced dramatically in the group receiving normal medical care. Serum sodium levels did not alter much in the midodrine group following therapy.

Also, Ali et al., 2016<sup>14</sup> and Obiedallah et al., 2017<sup>7</sup> agreed with our study that was on significant change in both serum sodium and potassium with the use of midodrine

It also observed that hyponatremia is a frequent complication of diuretic therapy in these patients which was also noted in our study where the baseline serum sodium in both groups was 128.2 and 126.7 respectively. (Patel et al., 2017)<sup>15</sup> showed different results where it found that oral

midodrine improve serum hyponatremia in cirrhotic patients but this study was for only 72 hours along with albumin infusion.

(Rai et al., 2017)<sup>11</sup> showed significant increase in serum sodium only with addition of tolvaptan. As regard urinary sodium level showed clinical significance between the two studied groups where it was higher in group II than in group I

Also, urinary sodium level significantly increased in midodrine group patients between the start and the end of the study which did not appear in control group.

Our results agreed with (Rai et al., 2017)<sup>11</sup> which was conducted for longer duration.

Also, (Singh et al., 2012)<sup>8</sup> revealed that After 1 and 3 months of therapy, midodrine considerably increased urinary sodium excretion, but this effect was no longer seen after 6 months.

mostly same results appeared in (Tandon et al., 2009)<sup>13</sup> where there was increase in urine sodium level only in spot test at the middle of the study with no further increase toward its end. (Angeli et al., 1998)<sup>12</sup> studied the acute effects of midodrine on renal hemodynamics agreed with our study although it studied the acute effects it suggested that natriuretic effects of midodrine reach plateau after a period of time.

The natriuretic effects of midodrine may be attributed to the suppression of renin angiotensin system (RAAS) as in (Tandon et al., 2009)<sup>13</sup>

On the other hand, natriuretic response to furosemide in patients with cirrhosis and ascites: effects of midodrine which was discussed by (Misra et al., 2010)<sup>16</sup> disagreed with our results, where it claimed that there was no effect of midodrine in urine sodium level but it was only studying the acute effects of midodrine on IV furosemide for 6 hours only.

As regard 24-hour urine volume, At the study's conclusion, it was shown to be greater in the midodrine group than in the control group. Furthermore, it rose in the midodrine group from the beginning to the end of the research, whereas the control group saw no change.

These results disagree with those of (Ali et al., 2014)<sup>10</sup> which found that there no difference in urine output in both midodrine group and placebo group. However, it should be noted that this study was conducted for shorter duration using smaller doses of Midodrine. On the other hand, (Singh et al., 2013)<sup>17</sup>, (Obiedallah et al., 2017)<sup>5</sup> and (Rai et al., 2017)<sup>11</sup> and agreed with our results as regard the increase in urine output after the use of Midodrine. Regarding liver enzymes, at whatever point in the trial, neither group differed significantly from the other.

Regarding total bilirubin, we discovered no statistically significant difference between the both groups at baseline and the conclusion of the research. Also, there was no difference in total bilirubin between the start and the end of the study in both midodrine and control groups. (Kalambokis et al., 2007)<sup>9</sup>, (Singh et al., 2012)<sup>8</sup> and (Obiedallah et al., 2017)<sup>5</sup> found the same results as regard total bilirubin. In conflict with these results, (Tandon et al., 2009)<sup>13</sup> found that total bilirubin significantly increased at 1 month of use of midodrine, octreotide-LAR and albumin but it returned to baseline level after 1-month post-treatment.

As regard INR, according to our research, there is no discernible distinction between the two categories at the base lines as well as at the end of the study. Also, there was no difference in INR between the start and the end of the study in both midodrine and control groups.

(Kalambokis et al., 2007)<sup>9</sup>, (Singh et al., 2012)<sup>8</sup> and (Obiedallah et al., 2017)<sup>5</sup> were also similar to our results as regard INR. (Kalil et al., 2018)<sup>18</sup> found that the use of midodrine was associated

with more worsening of INR and total bilirubin unlike our study. It should be noted that this study included patients waiting for liver transplant only.

As regard albumin level, no significant difference was found between groups either at the beginning or the conclusion of the investigation. There was also no variation between the two groups during the course of the study's duration. These results were supported (Kalambokis et al., 2007)<sup>9</sup>, (Oda et al., 2011)<sup>19</sup>, (Singh et al., 2013)<sup>17</sup> and (Ali et al., 2014)<sup>10</sup>

To the contrary, (Tandon et al., 2009)<sup>13</sup> found that synthetic functions of liver including albumin have been impaired with the use of midodrine despite using albumin infusion.

But this may be attributed to addition of octreotide which cause splanchnic vasoconstriction reducing the portal pressure and hepatic perfusion.

As regard serum creatinine, we found that there was no significant difference between the both groups at baseline as well as at the end of the study. However, there was slight increase in serum creatinine in control group unlike in midodrine group.

This was the case, according to the research conducted by (Kalambokis et al., 2005)<sup>20</sup>, (Tandon et al., 2009)<sup>13</sup> and (Singh et al., 2012)<sup>8</sup> where systemic hemodynamics improved but renal function did not alter after treatment and the effective circulating volume. on the other hand (Krag et al., 2007)<sup>21</sup> suggested more improve in renal functions with the use of vasopressors as terlipressin taking in consideration that it assessed renal functions by GFR which may be more accurate than serum creatinine

(Oda et al., 2011)<sup>19</sup> which studied the hemodynamic effects of midodrine in cirrhotic patients with ascites and without ascites found that there was improvement of renal hemodynamics in non-ascetic patients but it was not found in patients without refractory ascites, however it found noticeable rebound in the level of plasma renin activity after stoppage of midodrine. This was This can be explained by the massive activation of the renin-angiotensin-aldosterone system and the sympathetic nervous system, the increase in renal vascular resistance, the decrease in renal blood flow, and the relatively mild decrease in glomerular filtration rate that characterize this phase.

Except for one incidence of severe epistaxis in which the patient stopped using midodrine, no adverse events related to the drug have been reported. In contrast, 6 patients out of 59 reported stomach pain when taking midodrine for 6 months (Singh et al., 2012)<sup>8</sup>. However, they were all rather minor and did not necessitate a break in treatment. Similar findings were seen in a study by (Rai et al., 2017)<sup>11</sup>, in which only 2 of 13 individuals experienced moderate stomach discomfort that did not necessitate therapy termination.

- **In conclusion:** The addition of midodrine to SMT is associated with increase of urine volume and urine Na level and it is considered safe for patients with liver cirrhosis with little side effects

**One of the limitations** the small sample size of our investigation, short duration and the dosage form (3 tablets /8 hours) which was an obstacle for compliance of many patients.

## References

1-Sussman AN, Boyer TD. Management of refractory ascites and hepatorenal syndrome. Current gastroenterology reports. 2011 Feb;13:17-25.

2-Kashani A, Landaverde C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. QJM: An International Journal of Medicine. 2008 Feb 1;101(2):71-85..

- 3-** Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The impact of midodrine on outcomes in patients with intradialytic hypotension. *American journal of nephrology*. 2018;48(5):381-8.
- 4-** Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, Krag A, Laleman W, Gines P. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *Journal of hepatology*. 2018 Aug 1;69(2):406-60.
- 5-** Obiedallah AA, Abdelmohsen E, Kelani AI, Mousa M. Effect of midodrine in patients with liver cirrhosis and refractory ascites. *Am J Intern Med*. 2017;5:12-7.
- 6-** Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. *Hepatic medicine: evidence and research*. 2017 May 15:17-25.
- 7-** Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A, Salinas F, D'Aquino M, Sticca A, Gatta A. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. *Gut*. 2010 Jan 1;59(01):98-104.
- 8-** Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. *Journal of Hepatology*. 2012 Feb 1;56(2):348-54.
- 9-** Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. *Journal of hepatology*. 2007 Feb 1;46(2):213-21.
- 10-** Ali A, Farid S, Amin M, Kassem M, Al-Garem N. Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. *Hepatogastroenterology*. 2014 Oct 1;61(135):1915-24.
- 11-** Rai N, Singh B, Singh A, Vijayvergiya R, Sharma N, Bhalla A, Singh V. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. *Liver International*. 2017 Mar;37(3):406-14.
- 12-** Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L. Acute effects of the oral administration of midodrine, an  $\alpha$ -adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. *Hepatology*. 1998 Oct;28(4):937-43.
- 13-** Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. *Liver International*. 2009 Feb;29(2):169-74..
- 14-** Ali A, Farid S, Amin M, Kassem M, Al-Garem N, Al-Ghobashy M. Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers. *Clinical drug investigation*. 2016 Feb;36:147-55.
- 15-** Patel S, Nguyen DS, Rastogi A, Nguyen MK, Nguyen MK. Treatment of cirrhosis-associated hyponatremia with midodrine and octreotide. *Frontiers in medicine*. 2017 Mar 14;4:17.
- 16-** Misra VL, Vuppalanchi R, Jones D, Hamman M, Kwo PY, Kahi C, Chalasani N. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. *Alimentary pharmacology & therapeutics*. 2010 Oct;32(8):1044-50.
- 17-** Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. *Official journal of the American College of Gastroenterology| ACG*. 2013 Apr 1;108(4):560-7.

**18-** Kalil J, Klein J, Schadde E, Hertl M, Poirier J, Chan E. Midodrine conveys increased risk for waitlist mortality in liver transplant patients. *HPB*. 2018 Sep 1;20:S791.

**19-** Oda AM, Basuni AA, Badran HM, Aziz WF, Rewisha EA, Waked IA. Hemodynamic effects of 3 months of therapy with midodrine in cirrhotic patients with and without ascites. *Egyptian Liver Journal*. 2011 Jul 1;1(2):61-8.

**20-** Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. *Official journal of the American College of Gastroenterology| ACG*. 2005 Apr 1;100(4):879-85.

**21-** Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. *Hepatology*. 2007 Dec;46(6):1863-71.

**Table (1): Baseline characteristics in each group**

Baseline characteristics	Group I (n= 40)	Group II (n= 40)
<b>Body weight</b>		
Min. – Max.	70.0 – 120.0	66.0 – 117.0
Mean ± SD.	92.13 ± 12.17	89.10 ± 13.04
Median (IQR)	92.0(85.0 – 101.0)	88.50(77.0 – 96.0)
<b>Abdominal girth</b>		
Min. – Max.	86.0 – 139.0	89.0 – 149.0
Mean ± SD.	109.18 ± 16.79	120.4 ± 16.05
Median (IQR)	105.5(95.0 – 125.0)	121.5(108.5 – 134.0)
<b>Systolic blood pressure</b>		
Min. – Max.	90.0 – 120.0	90.0 – 120.0
Mean ± SD.	99.50 ± 8.15	99.0 ± 9.28
Median (IQR)	100.0(90.0 – 105.0)	100.0(90.0 – 110.0)
<b>Diastolic blood pressure</b>		
Min. – Max.	60.0 – 80.0	60.0 – 80.0
Mean ± SD.	68.0 ± 5.16	67.0 ± 5.64
Median (IQR)	70.0(65.0 – 70.0)	70.0(60.0 – 70.0)
<b>Hemoglobin</b>		
Min. – Max.	6.90 – 12.00	7.80 – 13.70
Mean ± SD.	9.54 ± 1.13	10.0 ± 1.27
Median (IQR)	9.60(8.9 – 10.2)	9.70(9.4 – 10.2)
<b>Platelets</b>		
Min. – Max.	46.0 – 160.0	40.0 – 492.0
Mean ± SD.	90.65 ± 22.40	128.5 ± 94.06
Median (IQR)	88.0(75.5 – 105.0)	105.0(74.5 – 141.5)
<b>Total leucocytic count</b>		
Min. – Max.	2.30 – 12.0	2.0 – 19.50
Mean ± SD.	6.64 ± 2.61	6.88 ± 3.74
Median (IQR)	6.20(4.7 – 8.0)	6.20(3.9 – 9.3)
<b>24 hour urine volume</b>		
Min. – Max.	800.0 – 1600.0	800.0 – 2500.0
Mean ± SD.	1142.50 ± 246.92	1230.0 ± 350.24
Median (IQR)	1200.0(1000.0 – 1200.0)	1200.0(1000.0 – 1400.0)
<b>Serum Na</b>		
Min. – Max.	116.0 – 137.0	117.5 – 138.0
Mean ± SD.	128.2 ± 5.60	126.7 ± 5.87
Median (IQR)	128.5(125.5 – 132.0)	128.0(122.0 – 130.5)

<b>Serum K</b>		
Min. – Max.	3.0 – 5.50	2.70 – 5.90
Mean ± SD.	4.16 ± 0.59	4.10 ± 0.74
Median (IQR)	4.0(3.8 – 4.5)	3.90(3.5 – 4.5)
<b>Urinary Na</b>		
Min. – Max.	10.50 – 90.0	10.50 – 315.0
Mean ± SD.	24.98 ± 17.23	42.23 ± 53.75
Median (IQR)	22.0(13.3 – 26.0)	26.0(13.8 – 41.5)
<b>Total Bilirubin</b>		
Min. – Max.	0.90 – 9.0	0.60 – 19.0
Mean ± SD.	3.40 ± 2.08	3.48 ± 3.49
Median (IQR)	2.30(1.8 – 4.8)	2.10(1.8 – 3.9)
<b>Serum creatinine</b>		
Min. – Max.	0.80 – 1.60	0.70 – 2.0
Mean ± SD.	1.14 ± 0.24	1.14 ± 0.28
Median (IQR)	1.20(1.0 – 1.3)	1.15(1.0 – 1.3)
<b>Urea</b>		
Min. – Max.	2.40 – 135.0	22.0 – 120.0
Mean ± SD.	54.74 ± 23.60	60.43 ± 28.99
Median (IQR)	46.50(42.0 – 65.0)	54.50(39.0 – 87.5)
<b>Albumin</b>		
Min. – Max.	1.80 – 3.20	1.80 – 3.30
Mean ± SD.	2.66 ± 0.31	2.58 ± 0.36
Median (IQR)	2.70(2.4 – 2.8)	2.55(2.3 – 2.8)
<b>Alanine transaminase</b>		
Min. – Max.	12.0 – 112.0	10.0 – 112.0
Mean ± SD.	36.33 ± 20.85	35.70 ± 22.97
Median (IQR)	33.0(22.0 – 44.5)	29.50(20.5 – 48.0)
<b>Aspartate transaminase</b>		
Min. – Max.	18.0 – 125.0	18.0 – 138.0
Mean ± SD.	52.80 ± 25.92	55.45 ± 29.84
Median (IQR)	45.0(37.5 – 68.5)	45.0(36.0 – 72.0)
<b>International normalized ratio</b>		
Min. – Max.	1.20 – 2.0	1.0 – 2.10
Mean ± SD.	1.61 ± 0.21	1.59 ± 0.26
Median (IQR)	1.60(1.5 – 1.8)	1.60(1.4 – 1.8)

Table (2): Comparison between the two studied groups according to general examination at the end of the study.

General examination at the end	Group I (n = 37)		Group II (n = 37)		$\chi^2$	P
	No.	%	No.	%		
<b>Conscious level</b>						
Conscious	29	57.5	35	94.6		

Hepatic encephalopathy	8	24.3	2	5.4		
<b>Frequency of tapping (months)</b>						
Min. – Max.	0.0 – 2.0		0.0 – 2.0		U= 498.50*	0.021*
Mean ± SD.	0.92 ± 0.60		0.59 ± 0.55			
Median (IQR)	1.0(1.0 – 2.0)		1.0(1.0 – 2.0)			
<b>Body weight</b>						
Min. – Max.	63.0 – 120.0		65.0 – 116.0		t= 1.879	0.064
Mean ± SD.	91.65 ± 12.82		86.0 ± 13.04			
Median (IQR)	92.0(86.0 – 101.0)		86.0(77.0 – 91.0)			
<b>Abdominal girth</b>						
Min. – Max.	84.0 – 138.0		84.0 – 145.0		t= 2.082*	0.041*
Mean ± SD.	109.2 ± 16.11		117.0 ± 15.94			
Median (IQR)	105.0(95.0 – 126.0)		116.0(106.0 – 128.0)			
<b>Lower limb odema</b>						
No	1	2.6	0	0.0	$\chi^2= 15.671^*$	<sup>MC</sup> p <0.001*
Mild	4	10.5	19	51.4		
Moderate	29	76.3	15	40.5		
Marked	4	10.5	3	8.1		

IQR: Inter quartile range

SD: Standard deviation

t: Student t-test

$\chi^2$ : Chi square test

MC: Monte Carlo U: Mann Whitney test

p: p value for comparing between the studied groups\*: Statistically significant at  $p \leq 0.05$

Group I: refractory ascites on traditional treatment

Group II: refractory ascites on traditional treatment plus Midodrine

**Table (3): Comparison between the start and the end of the study according to general examination in group I and II**

Group I						
General examination	The start (n = 37)		The end (n = 37)		Test of Sig.	p
	No.	%	No.	%		
<b>Conscious level</b>						
No hepatic encephalopathy	31	83.8	35	94.6		
Hepatic encephalopathy	6	16.2	2	5.4		
<b>Frequency of tapping (month)</b>						

Min. – Max.	0.0 – 3.0		0.0 – 2.0		Z= 3.084*	0.002*
Mean ± SD.	1.49 ± 0.77		0.92 ± 0.60			
Median (IQR)	1.0(1.0 – 2.0)		1.0(1.0 – 2.0)			
<b>Body weight</b>						
Min. – Max.	70.0 – 120.0		63.0 – 120.0		t= 1.210	0.234
Mean ± SD.	92.51 ± 12.09		91.65 ± 12.82			
Median (IQR)	92.0 (86.0 – 100.0)		92.0(86.0 – 101.0)			
<b>Abdominal girth</b>						
Min. – Max.	86.0 – 139.0		84.0 – 138.0		t= 1.182	0.245
Mean ± SD.	109.70 ± 16.73		109.2 ± 16.11			
Median (IQR)	106.0 (95.0 – 125.0)		105.0(95.0 – 126.0)			
<b>Lower limb odema</b>						
No	0	0.0	1	2.6	MH= 40.0*	<0.001*
Mild	0	0.0	4	10.5		
Moderate	22	59.5	29	76.3		
Marked	15	40.5	4	10.5		
<b>Group II</b>						
<b>General examination</b>	<b>The start (n = 37)</b>		<b>The end (n = 37)</b>		<b>Test of Sig.</b>	<b>P</b>
	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>		
<b>Conscious level</b>						
No hepatic encephalopathy	29	78.4	35	49.6		
Hepatic encephalopathy	8	21.6	2	5.4		
<b>Frequency of tapping (month)</b>						
Min. – Max.	0.0 – 4.0		0.0 – 2.0		Z=4.542*	<0.001*
Mean ± SD.	1.81 ± 1.20		0.59 ± 0.55			
Median (IQR)	2.0(1.0 – 2.0)		1.0(0.0 – 1.0)			
<b>Body weight</b>						
Min. – Max.	66.0 – 117.0		65.0 – 116.0		t=	<0.001*

Mean ± SD.	88.54 ± 13.36		86.0 ± 13.04		5.946*	
Median (IQR)	88.0 (77.0 – 95.0)		86.0(77.0 – 91.0)			
<b>Abdominal girth</b>						
Min. – Max.	89.0 – 149.0		84.0 – 145.0		t= 6.274*	<0.001*
Mean ± SD.	119.57 ± 16.40		117.0 ± 15.94			
Median (IQR)	118.0(106.0 – 134.0)		116.0(106.0 – 128.0)			
<b>Lower limb odema</b>						
No	0	0.0	0	0.0	MH= 50.0*	<0.001*
Mild	0	0.0	19	51.4		
Moderate	23	62.2	15	40.5		
Marked	14	37.8	3	8.1		

IQR: Inter quartile range

SD: Standard deviation

t: Paired t-test

MH: Marginal Homogeneity Test

p: p value for comparing between **Start** and **End** \*: Statistically significant at  $p \leq 0.05$

Group I: refractory ascites on traditional treatment

Group II: refractory ascites on traditional treatment plus Midodrine

**Table (4): Comparison between the two studied groups according to the laboratory data at the end of the study:**

Lab (at the end)	Group I (n = 37)	Group II (n = 37)	Test of Sig.	P
<b>Serum creatinine</b>				
Min. – Max.	0.80 – 2.0	0.60 – 2.30	U= 618.50	0.472
Mean ± SD.	1.24 ± 0.30	1.20 ± 0.40		
Median (IQR)	1.20(1.0 – 1.4)	1.10(1.0 – 1.3)		
<b>Urea</b>				
Min. – Max.	26.0 – 170.0	16.0 – 200.0	U= 618.00	0.472
Mean ± SD.	56.94 ± 24.93	68.16 ± 40.30		
Median (IQR)	48.0(44.0 – 65.0)	53.0(40.0 – 98.0)		
<b>Albumin</b>				
Min. – Max.	2.20 – 3.20	2.0 – 3.50	U= 669.00	0.866
Mean ± SD.	2.61 ± 0.27	2.63 ± 0.33		
Median (IQR)	2.50(2.4 – 2.8)	2.50(2.4 – 2.7)		
<b>Alanine transaminase</b>				
Min. – Max.	12.0 – 150.0	12.0 – 88.0	U= 572.50	0.225
Mean ± SD.	41.73 ± 26.84	34.68 ± 17.77		
Median (IQR)	36.0(24.0 – 45.0)	28.0(22.0 – 43.0)		
<b>Aspartate</b>				

<b>transaminase</b>				
Min. – Max.	15.0 – 450.0	16.0 – 164.0	U= 628.50	0.544
Mean ± SD.	66.86 ± 74.22	54.11 ± 28.52		
Median (IQR)	45.0(38.0 – 66.0)	44.0(38.0 – 64.0)		
<b>International normalized ratio</b>				
Min. – Max.	1.0 – 1.90	1.20 – 2.50	t= 0.762	0.449
Mean ± SD.	1.56 ± 0.22	1.61 ± 0.26		
Median (IQR)	1.60(1.5 – 1.8)	1.60(1.4 – 1.7)		
<b>Hemoglobin</b>				
Min. – Max.	7.90 – 12.80	8.0 – 13.0	U= 1.752	0.085
Mean ± SD.	9.49 ± 0.90	9.95 ± 1.32		
Median (IQR)	9.50(9.0 – 10.0)	9.50(9.2 – 10.7)		
<b>Platelets</b>				
Min. – Max.	42.0 – 126.0	44.0 – 442.0	t= 2.079	0.044*
Mean ± SD.	90.62 ± 19.48	122.0 ± 89.73		
Median (IQR)	89.0(75.0 – 105.0)	92.0(82.0 – 108.0)		
<b>Total leucocytic count</b>				
Min. – Max.	1.90 – 12.0	2.80 – 10.80	U= 678.50	0.948
Mean ± SD.	6.74 ± 2.87	6.49 ± 2.44		
Median (IQR)	6.50(4.4 – 9.2)	5.30(4.8 – 8.2)		
<b>24 hour urine volume</b>				
Min. – Max.	800.0 – 1900.0	1000.0 – 2500.0	U= 421.50	0.004*
Mean ± SD.	1264.9 ± 311.1	1527.0 ± 384.2		
Median (IQR)	1200.0 (1000.0 – 1500.0)	1500.0 (1200.0 – 1600.0)		
<b>Serum Na</b>				
Min. – Max.	118.0 – 137.50	116.0 – 137.0	t= 0.011	0.992
Mean ± SD.	127.0 ± 5.25	127.0 ± 5.72		
Median (IQR)	128.0(122.0 – 130.0)	128.0(125.0 – 130.0)		
<b>Serum K</b>				
Min. – Max.	2.80 – 5.60	3.20 – 5.80	t= 1.678	0.098
Mean ± SD.	4.05 ± 0.67	4.31 ± 0.68		
Median (IQR)	4.0(3.7 – 4.2)	4.40(3.7 – 4.9)		
<b>Urinary Na</b>				
Min. – Max.	12.0 – 112.0	16.0 – 360.0	U= 278.00*	<0.001*
Mean ± SD.	31.73 ± 22.90	82.70 ± 68.12		
Median (IQR)	22.50(18.0 – 35.0)	72.0(32.5 – 125.0)		
<b>Total Bilirubin</b>				
Min. – Max.	1.20 – 7.50	0.80 – 10.70	U= 528.500	0.091
Mean ± SD.	3.26 ± 1.66	2.82 ± 2.17		
Median (IQR)	2.50(2.0 – 4.5)	2.10(1.8 – 3.0)		

IQR: Inter quartile range

SD: Standard deviation

t: Student t-test

U: Mann Whitney test

p: p value for comparing between the studied groups \*: Statistically significant at  $p \leq 0.05$

**Table (5): Comparison between the start and the end of the study according to laboratory data in group I and II**

<b>Group I</b>				
<b>Lab</b>	<b>The start (n = 37)</b>	<b>The end (n = 37)</b>	<b>Test of Sig.</b>	<b>p</b>
<b>Serum creatinine</b>				
Min. – Max.	0.80 – 1.60	0.80 – 2.0	Z= 2.310*	0.021*
Mean ± SD.	1.12 ± 0.23	1.24 ± 0.30		
Median (IQR)	1.10 (1.0 – 1.20)	1.20(1.0 – 1.4)		
<b>Urea</b>				
Min. – Max.	2.40 – 135.0	26.0 – 170.0	Z= 0.752	0.452
Mean ± SD.	53.96 ± 24.04	56.94 ± 24.93		
Median (IQR)	45.0 (42.0 – 65.0)	48.0(44.0 – 65.0)		
<b>Albumin</b>				
Min. – Max.	1.80 – 3.20	2.20 – 3.20	Z= 1.007	0.314
Mean ± SD.	2.65 ± 0.31	2.61 ± 0.27		
Median (IQR)	2.70 (2.40 – 2.80)	2.50(2.4 – 2.8)		
<b>Alanine transaminase</b>				
Min. – Max.	12.0 – 112.0	12.0 – 150.0	Z= 1.319	0.187
Mean ± SD.	37.46 ± 21.15	41.73 ± 26.84		
Median (IQR)	33.0 (22.0 – 45.0)	36.0(24.0 – 45.0)		
<b>Aspartate transaminase</b>				
Min. – Max.	18.0 – 125.0	15.0 – 450.0	Z= 0.327	0.743
Mean ± SD.	53.57 ± 26.30	66.86 ± 74.22		
Median (IQR)	45.0 (39.0 – 72.0)	45.0(38.0 – 66.0)		
<b>International normalized ratio</b>				
Min. – Max.	1.20 – 2.0	1.0 – 1.90	t= 0.687	0.496
Mean ± SD.	1.59 ± 0.21	1.56 ± 0.22		
Median (IQR)	1.60 (1.40 – 1.80)	1.60(1.5 – 1.8)		
<b>Hemoglobin</b>				
Min. – Max.	6.90 – 12.0	7.90 – 12.80	t= 0.475	0.638
Mean ± SD.	9.58 ± 1.09	9.49 ± 0.90		
Median (IQR)	9.60 (8.90 – 10.20)	9.50(9.0 – 10.0)		
<b>Platelets</b>				
Min. – Max.	46.0 – 160.0	42.0 – 126.0	t= 0.338	0.737
Mean ± SD.	89.24 ± 22.34	90.62 ± 19.48		
Median (IQR)	85.0 (75.0 – 104.0)	89.0(75.0 – 105.0)		
<b>Total leucocytic count</b>				
Min. – Max.	2.30 – 11.0	1.90 – 12.0	Z= 0.204	0.838
Mean ± SD.	6.56 ± 2.54	6.74 ± 2.87		
Median (IQR)	6.20 (4.70 – 8.0)	6.50(4.4 – 9.2)		
<b>24 hour urine volume</b>				
Min. – Max.	800.0 – 1600.0	800.0 – 1900.0	Z= 0.054	0.054

Mean ± SD.	1137.84 ± 256.42	1264.9 ± 311.1	1.924	
Median (IQR)	1200.0 (1000.0 – 1200.0)	1200.0 (1000.0 – 1500.0)		
<b>Serum Na</b>				
Min. – Max.	116.0 – 137.0	118.0 – 137.50	t= 1.500	0.142
Mean ± SD.	128.59 ± 5.18	127.0 ± 5.25		
Median (IQR)	129.0 (126.0 – 132.0)	128.0(122.0 – 130.0)		
<b>Serum K</b>				
Min. – Max.	3.0 – 5.50	2.80 – 5.60	t= 0.423	0.675
Mean ± SD.	4.11 ± 0.57	4.05 ± 0.67		
Median (IQR)	4.0 (3.70 – 4.50)	4.0(3.7 – 4.2)		
<b>Urinary Na</b>				
Min. – Max.	10.50 – 90.0	12.0 – 112.0	Z= 1.936	0.053
Mean ± SD.	25.61 ± 17.69	31.73 ± 22.90		
Median (IQR)	22.0 (15.0 – 26.0)	22.50(18.0 – 35.0)		
<b>Total Bilirubin</b>				
Min. – Max.	0.90 – 8.0	1.20 – 7.50	Z= 0.707	0.480
<b>Group II</b>				
<b>Lab</b>	<b>The start (n = 37)</b>	<b>The end (n = 37)</b>	<b>Test of Sig.</b>	<b>p</b>
<b>Hemoglobin</b>				
Min. – Max.	7.80 – 13.70	8.0 – 13.0	t= 0.704	0.486
Mean ± SD.	10.06 ± 1.31	9.95 ± 1.32		
Median (IQR)	9.80 (9.40 – 10.20)	9.50(9.2 – 10.7)		
<b>Platelets</b>				
Min. – Max.	40.0 – 492.0	44.0 – 442.0	t= 0.928	0.359
Mean ± SD.	130.27 ± 97.41	122.0 ± 89.73		
Median (IQR)	105.0 (73.0 – 143.0)	92.0 (82.0 – 108.0)		
<b>Total leucocytic count</b>				
Min. – Max.	2.0 – 19.50	2.80 – 10.80	Z= 1.117	0.264
Mean ± SD.	7.12 ± 3.79	6.49 ± 2.44		
Median (IQR)	6.30 (4.30 – 9.50)	5.30(4.8 – 8.2)		
<b>24 hour urine volume</b>				
Min. – Max.	800.0 – 2500.0	1000.0 – 2500.0	Z= 4.643*	<0.001*
Mean ± SD.	1227.03 ± 350.91	1527.0 ± 384.2		
Median (IQR)	1200.0 (1000.0 – 1400.0)	1500.0 (1200.0 – 1600.0)		
<b>Serum Na</b>				
Min. – Max.	117.50 – 138.0	116.0 – 137.0	t= 0.040	0.968
Mean ± SD.	126.99 ± 5.88	127.0 ± 5.72		
Median (IQR)	128.0 (122.0 – 131.0)	128.0(125.0 – 130.0)		
<b>Serum K</b>				
Min. – Max.	2.70 – 5.90	3.20 – 5.80	t= 1.574	0.124
Mean ± SD.	4.13 ± 0.76	4.31 ± 0.68		
Median (IQR)	3.90 (3.50 – 4.50)	4.40(3.7 – 4.9)		
<b>Urinary Na</b>				
Min. – Max.	10.50 – 315.0	16.0 – 360.0	Z= 4.156*	<0.001*
Mean ± SD.	42.97 ± 55.21	82.70 ± 68.12		
Median (IQR)	29.0 (15.0 – 38.0)	72.0(32.5 – 125.0)		
<b>Total Bilirubin</b>				

Min. – Max.	0.60 – 19.0	0.80 – 10.70	Z= 0.729	0.466
Mean ± SD.	3.42 ± 3.59	2.82 ± 2.17		
Median (IQR)	2.10 (1.80 – 3.50)	2.10(1.8 – 3.0)		
Mean ± SD.	3.27 ± 1.94	3.26 ± 1.66		
Median (IQR)	2.30 (1.80 – 4.80)	2.50(2.0 – 4.5)		
<b>Serum creatinine</b>				
Min. – Max.	0.70 – 2.0	0.60 – 2.30	Z= 1.127	0.260
Mean ± SD.	1.14 ± 0.29	1.20 ± 0.40		
Median (IQR)	1.10 (1.0 – 1.30)	1.10(1.0 – 1.3)		
<b>Urea</b>			Z= 1.260	0.208
Min. – Max.	22.0 – 120.0	0.60 – 2.30		
Mean ± SD.	61.16 ± 30.01	1.20 ± 0.40		
Median (IQR)	54.0 (38.0 – 90.0)	1.10(40.0 – 98.0)		
<b>Albumin</b>			Z= 0.507	0.612
Min. – Max.	1.80 – 3.30	2.0 – 3.50		
Mean ± SD.	2.58 ± 0.37	2.63 ± 0.33		
Median (IQR)	2.50 (2.30 – 2.80)	2.50(2.4 – 2.7)		
<b>Alanine transaminase</b>			Z= 0.771	0.441
Min. – Max.	10.0 – 112.0	12.0 – 88.0		
Mean ± SD.	36.65 ± 23.57	34.68 ± 17.77		
Median (IQR)	31.0 (22.0 – 51.0)	28.0(22.0 – 43.0)		
<b>Aspartate transaminase</b>			Z= 0.632	0.528
Min. – Max.	18.0 – 138.0	16.0 – 164.0		
Mean ± SD.	56.16 ± 30.30	54.11 ± 28.52		
Median (IQR)	45.0 (37.0 – 72.0)	44.0(38.0 – 64.0)		
<b>International normalized ratio</b>			t= 0.519	0.607
Min. – Max.	1.0 – 2.10	1.20 – 2.50		
Mean ± SD.	1.59 ± 0.25	1.61 ± 0.26		
Median (IQR)	1.60 (1.40 – 1.80)	1.60(1.4 – 1.7)		

IQR: Inter quartile range

SD: Standard deviation

t: Paired t-test

Z: Wilcoxon signed ranks test

p: p value for comparing between **Start** and **End** \*: Statistically significant at  $p \leq 0.05$




Fig. 1. Flowchart showing the disposition of the patients included in the study